Can a simple arthritis drug tame CAR-T's dangerous brain side effects?
NCT ID NCT04150913
First seen Dec 26, 2025 · Last updated May 21, 2026 · Updated 19 times
Summary
This study tested whether adding anakinra (a drug used for arthritis) to standard CAR-T cell therapy could prevent serious brain and nerve side effects in people with hard-to-treat non-Hodgkin lymphoma. Fifteen participants received both treatments. The goal was to see if the combination reduced confusion, seizures, and other neurotoxicity symptoms while still fighting the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.